1+ day, 9+ hour ago   (488+ words) Exploring the complex legacy of Oliver Sacks, this article examines the blurred lines between truth and fiction in his case studies. PSYCHIATRIC VIEWS ON THE DAILY NEWS Yesterday, I wrote my catch-up column on psychiatrists who passed away in 2025 that…...

2+ day, 10+ hour ago   (305+ words) Lipocine's LPCN 1154 shows promise in treating postpartum depression, with a strong safety profile and potential for rapid relief in outpatient settings. Lipocine today announced the completion of a scheduled independent Data Safety Monitoring Board (DSMB) review of its ongoing phase…...

2+ day, 18+ hour ago   (556+ words) Explore the diverse legacies of influential psychiatrists who shaped mental health, from poetry to cooking, highlighting their profound impact on society. PSYCHIATRIC VIEWS ON THE DAILY NEWS Roger B. Granet, MD: Psychiatrist, Author, Poet, and Basketballer Dr Granet passed away on February…...

1+ week, 5+ day ago   (228+ words) Biohaven's BHV-7000 fails to reduce depressive symptoms in a phase 2 proof-of-concept study. Biohaven today reported results from a phase 2 proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorder (MDD): BHV-7000 did not demonstrate a reduction of depressive symptoms as…...

2+ mon, 6+ day ago   (272+ words) Johnson & Johnson's Caplyta gains FDA approval as an adjunctive treatment for major depressive disorder, offering hope for improved patient outcomes. The US Food and Drug Administration (FDA) has approved Johnson & Johnson's'lumateprone (Caplyta) as an adjunctive therapy for the treatment of…...

2+ mon, 1+ week ago   (487+ words) Submit to our writing contest for the opportunity to win publication in Psychiatric Times and a $500 prize! The PRiSM Diagnostic Instrument is available here. 1. Articles can be in the form of a brief research report, a case study or case…...